thalidomide has been researched along with Myasthenia Gravis in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sakano, S | 1 |
| Matsuyama, H | 1 |
| Ishikawa, H | 1 |
| Shindo, A | 1 |
| Ii, Y | 1 |
| Matsuura, K | 1 |
| Mizutani, M | 1 |
| Kawada, N | 1 |
| Tomimoto, H | 1 |
| Li, S | 1 |
| Cao, Y | 1 |
| Li, L | 1 |
| Zhang, H | 1 |
| Lu, X | 1 |
| Bo, C | 1 |
| Kong, X | 1 |
| Liu, Z | 1 |
| Chen, L | 1 |
| Liu, P | 1 |
| Jiao, Y | 1 |
| Wang, J | 1 |
| Ning, S | 1 |
| Wang, L | 1 |
| Crain, E | 1 |
| McIntosh, KR | 1 |
| Gordon, G | 1 |
| Pestronk, A | 1 |
| Drachman, DB | 1 |
3 other studies available for thalidomide and Myasthenia Gravis
| Article | Year |
|---|---|
Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report.
Topics: Antineoplastic Agents; Autoantibodies; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Myas | 2020 |
Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
Topics: Adalimumab; Carnosine; Databases, Genetic; Databases, Pharmaceutical; Drug Repositioning; Etanercept | 2019 |
The effect of thalidomide on experimental autoimmune myasthenia gravis.
Topics: Animals; Antibody Formation; Autoantibodies; Autoimmune Diseases; Drug Evaluation, Preclinical; Immu | 1989 |